- Market Realist•13 hours ago
Eli Lilly & Co.'s (LLY) top line rose 7% to ~$5.8 billion for 4Q16, driven by volume growth of pharmaceutical products such as Erbitux, Trulicity, Humalog, and Cyramza.
- American City Business Journals•16 hours ago
Harvard Pilgrim Health Care has negotiated new payment contracts with two pharmaceutical companies for expensive drugs, progressing a new kind of payment model that could save millions of dollars down the line. If not, the insurer receives a rebate from the pharmaceutical company, which trickles down into more stable premiums for members. “If you think about it, this is considered groundbreaking but it shouldn’t be,” said Michael Sherman, chief medical officer and senior vice president for health services at Harvard Pilgrim.
- Investopedia•20 hours ago
The deal serves a dual purpose: Deliver better value to patients and preserve the drug's market share.
LLY : Summary for Eli Lilly and Company Common St - Yahoo Finance
Eli Lilly and Company (LLY)
NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
|Day's Range||81.14 - 82.88|
|52 Week Range||64.18 - 83.79|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||32.02|
|Dividend & Yield||2.08 (2.57%)|
|1y Target Est||N/A|